276 related articles for article (PubMed ID: 28129490)
21. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis.
Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Franceschini F; Quinzanini M; Tincani A; Ross SJ; Chan JY; Pauley BA; Chan EK; Satoh M
Arthritis Res Ther; 2012 Apr; 14(2):R97. PubMed ID: 22546500
[TBL] [Abstract][Full Text] [Related]
22. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis.
Cao H; Parikh TN; Zheng J
Clin Rheumatol; 2009 Aug; 28(8):979-84. PubMed ID: 19294477
[TBL] [Abstract][Full Text] [Related]
23. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
24. [Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017].
Victor J; Zanardo L; Héron-Mermin D; Poursac N; Solé G; Bordes C; Duffau P
Rev Med Interne; 2019 Feb; 40(2):70-81. PubMed ID: 30527961
[TBL] [Abstract][Full Text] [Related]
25. Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria.
Didona D; Juratli HA; Scarsella L; Keber U; Eming R; Hertl M
Eur J Dermatol; 2020 Jun; 30(3):279-288. PubMed ID: 32666928
[TBL] [Abstract][Full Text] [Related]
26. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.
Valenzuela A; Chung L; Casciola-Rosen L; Fiorentino D
JAMA Dermatol; 2014 Jul; 150(7):724-9. PubMed ID: 24869801
[TBL] [Abstract][Full Text] [Related]
27. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
Fiorentino DF; Kuo K; Chung L; Zaba L; Li S; Casciola-Rosen L
J Am Acad Dermatol; 2015 Mar; 72(3):449-55. PubMed ID: 25595720
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy.
Kaji K; Fujimoto M; Hasegawa M; Kondo M; Saito Y; Komura K; Matsushita T; Orito H; Hamaguchi Y; Yanaba K; Itoh M; Asano Y; Seishima M; Ogawa F; Sato S; Takehara K
Rheumatology (Oxford); 2007 Jan; 46(1):25-8. PubMed ID: 16728436
[TBL] [Abstract][Full Text] [Related]
29. [Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case].
Girard C; Vincent T; Bessis D
Ann Dermatol Venereol; 2013 Oct; 140(10):628-34. PubMed ID: 24090894
[TBL] [Abstract][Full Text] [Related]
30. Ten-year experience of juvenile dermatomyositis: a retrospective study.
Chiu SK; Yang YH; Wang LC; Chiang BL
J Microbiol Immunol Infect; 2007 Feb; 40(1):68-73. PubMed ID: 17332910
[TBL] [Abstract][Full Text] [Related]
31. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.
Nguyen M; Do V; Yell PC; Jo C; Liu J; Burns DK; Wright T; Cai C
Acta Neuropathol Commun; 2020 Aug; 8(1):125. PubMed ID: 32758284
[TBL] [Abstract][Full Text] [Related]
32. Anti-transcription intermediary factor-1γ/α/β antibody-positive dermatomyositis associated with multiple panniculitis lesions.
Yanaba K; Tanito K; Hamaguchi Y; Nakagawa H
Int J Rheum Dis; 2017 Nov; 20(11):1831-1834. PubMed ID: 26258542
[No Abstract] [Full Text] [Related]
33. Periorbital edema as the presenting sign of dermatomyositis.
Hall VC; Keeling JH; Davis MD
Int J Dermatol; 2003 Jun; 42(6):466-7. PubMed ID: 12786876
[TBL] [Abstract][Full Text] [Related]
34. Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies.
Mugii N; Hasegawa M; Matsushita T; Hamaguchi Y; Oohata S; Okita H; Yahata T; Someya F; Inoue K; Murono S; Fujimoto M; Takehara K
PLoS One; 2016; 11(5):e0154746. PubMed ID: 27167831
[TBL] [Abstract][Full Text] [Related]
35. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis.
Hoesly PM; Sluzevich JC; Jambusaria-Pahlajani A; Lesser ER; Heckman MG; Abril A
J Am Acad Dermatol; 2019 May; 80(5):1364-1370. PubMed ID: 30458207
[TBL] [Abstract][Full Text] [Related]
36. [Extensive digital necrosis during dermatomyositis associated with MDA-5 antibodies].
Charbit L; Bursztejn AC; Mohamed S; Kaminsky P; Lerondeau B; Barbaud A; Deibener-Kaminsky J; Schmutz JL
Ann Dermatol Venereol; 2016; 143(8-9):537-42. PubMed ID: 27157503
[TBL] [Abstract][Full Text] [Related]
37. [Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies].
Gerfaud-Valentin M; Ahmad K; Piegay F; Fabien N; Raphanel B; Cordier JF; Cottin V
Rev Mal Respir; 2014 Nov; 31(9):849-53. PubMed ID: 25433590
[TBL] [Abstract][Full Text] [Related]
38. A single-centre cohort study on cutaneous manifestations of antinuclear matrix protein 2 antibody-positive dermatomyositis.
Okochi S; Ogawa-Momohara M; Muro Y; Dittmer MR; Akiyama M
Clin Exp Dermatol; 2020 Jul; 45(5):591-593. PubMed ID: 31808188
[No Abstract] [Full Text] [Related]
39. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
40. Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.
Wolstencroft PW; Fiorentino DF
Curr Rheumatol Rep; 2018 Apr; 20(5):28. PubMed ID: 29637414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
